These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16494649)

  • 1. Measles, mumps and rubella -- the urologist's perspective.
    Singh R; Mostafid H; Hindley RG
    Int J Clin Pract; 2006 Mar; 60(3):335-9. PubMed ID: 16494649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The increasing incidence of mumps orchitis: a comprehensive review.
    Davis NF; McGuire BB; Mahon JA; Smyth AE; O'Malley KJ; Fitzpatrick JM
    BJU Int; 2010 Apr; 105(8):1060-5. PubMed ID: 20070300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we missing mumps epididymo-orchitis?
    Emerson C; Dinsmore WW; Quah SP
    Int J STD AIDS; 2007 May; 18(5):341-2. PubMed ID: 17524197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies.
    Jalal H; Bahadur G; Knowles W; Jin L; Brink N
    J Med Virol; 2004 May; 73(1):147-50. PubMed ID: 15042662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mumps: a resurgent disease with protean manifestations.
    Senanayake SN
    Med J Aust; 2008 Oct; 189(8):456-9. PubMed ID: 18928441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella.
    Davidkin I; Jokinen S; Paananen A; Leinikki P; Peltola H
    J Infect Dis; 2005 Mar; 191(5):719-23. PubMed ID: 15688285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orchitis following mumps vaccination in an adult.
    Kuczyk MA; Denil J; Thon WF; Djamilian M; Truss M; Schlick R; Jonas U
    Urol Int; 1994; 53(3):179-80. PubMed ID: 7645149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mumps awareness.
    Pilkington R
    Br Dent J; 2008 Aug; 205(3):114. PubMed ID: 18690172
    [No Abstract]   [Full Text] [Related]  

  • 11. Mumps epididymitis.
    HARTMAN HE
    J Urol; 1958 Jun; 79(6):999-1000. PubMed ID: 13540000
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term persistence of antibodies after one or two doses of MMR-vaccine.
    Vandermeulen C; Mathieu R; Geert LR; Pierre VD; Karel H
    Vaccine; 2007 Sep; 25(37-38):6672-6. PubMed ID: 17692439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mumps epididymo-orchitis and its treatment with cortisone. Report of a controlled trial.
    KOCEN RS; CRITCHLEY E
    Br Med J; 1961 Jul; 2(5243):20-4. PubMed ID: 13757310
    [No Abstract]   [Full Text] [Related]  

  • 18. Mumps vaccine performance among university students during a mumps outbreak.
    Cortese MM; Jordan HT; Curns AT; Quinlan PA; Ens KA; Denning PM; Dayan GH
    Clin Infect Dis; 2008 Apr; 46(8):1172-80. PubMed ID: 18444852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epididymo-orchitis and epididymitis: a review of causes and management of unusual forms.
    Hagley M
    Int J STD AIDS; 2003 Jun; 14(6):372-7; quiz 378. PubMed ID: 12816663
    [No Abstract]   [Full Text] [Related]  

  • 20. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
    Bernsen RM; van der Wouden JC
    Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.